Risks
4 risks
Risk Intelligence
Dependence on US FDA approvals for complex launches
View Risks →
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Reddy's delivered a strong Q2 FY25 with consolidated revenues of ₹8,016 crore, up 17% YoY, driven by broad-based growth across all markets. EBITDA margin stood at 28.4% (29.1% adjusted for one-time costs), while PAT (ex-NCI) was ₹1,255 crore. Key growth drivers included robust performance in North America (16% YoY), India (18% YoY), and Russia (27% YoY in constant currency). The company completed the Nicotinell acquisition and Nestlé JV, and is investing in high-value generics, biosimilars (Abatacept launch targeted early 2027), and GLP-1 APIs. Management expects SG&A to be 27.5%-28% of sales for FY25 and R&D at 8.5%-9%. A key risk is the dependency on US FDA approvals for complex product launches and potential pricing erosion in generics.
डॉ. रेड्डीज ने दूसरी तिमाही में 8,016 करोड़ रुपये का कारोबार किया, जो पिछले साल से 17% ज्यादा है। कंपनी का मुनाफा 1,255 करोड़ रुपये रहा। अमेरिका, भारत और रूस में बिक्री बढ़ने से यह मजबूत प्रदर्शन हुआ। कंपनी ने निकोटिनेल और नेस्ले के साथ साझेदारी की है। वह महंगी दवाओं और बायोसिमिलर पर काम कर रही है। खर्च बिक्री का 27.5-28% और रिसर्च पर 8.5-9% रहने का अनुमान है। मुख्य जोखिम अमेरिकी मंजूरी में देरी और जेनेरिक दवाओं के दाम गिरने का है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
North America Generics Revenue Growth (YoY)
16%
+16% YoY
North America generics revenue grew 16% YoY, driven by volume growth offsetting single-digit price erosion.
India Business Revenue Growth (YoY)
18%
+18% YoY
India business grew 18% YoY, aided by Sanofi vaccine portfolio and new brand launches.
Russia Business Growth (Constant Currency)
27%
+27% YoY
Russia business grew 27% YoY in constant currency, driven by market share gains.
R&D Spend as % of Sales
9.1%
+115 bps YoY
R&D spend at 9.1% of sales, up 115 bps YoY, focused on complex generics, biosimilars, and novel assets.
What Changed vs Last Quarter
NEW
Normalized ETR around 25% for FY25
Management expects the normalized effective tax rate to be around 25% for the fiscal year.
NEW
Abatacept biosimilar launch in early calendar 2027
Management guided that the Abatacept biosimilar is expected to launch in early calendar 2027, with phase III trials nearly complete.
UPDATED
SG&A spend to be 27.5%-28% of sales for FY25
Management expects SG&A as a percentage of sales to be in the range of 27.5%-28% for the full fiscal year.
UPDATED
R&D spend to be 8.5%-9% of sales for FY25
Management expects R&D investment to be in the range of 8.5%-9% of sales for the full fiscal year.
DROPPED
Effective tax rate of 24%-25% for FY25
Normal effective tax rate expected to be in the range of 24% to 25% for the fiscal year.
DROPPED
US generics to grow in single digits for FY25
Management expects North America generics to continue growing in single digits on a year-over-year basis, compensating for price erosion.
NEW RISK
Dependence on US FDA approvals for complex launches
Launch of high-value products like Rituximab biosimilar in the US depends on FDA approval, which is uncertain and could be delayed.
NEW RISK
Revlimid revenue sustainability
Revenue from lenalidomide (Revlimid) is subject to confidential agreements and competitive pressures; management declined to provide specific guidance on future sales.
NEW RISK
Currency risk in Russia
Russia business faces unfavorable forex movements; despite hedging, devaluation could impact reported revenues.
NEW RISK
Impairment risk from supply chain issues
A product faced procurement constraints from contract manufacturers, leading to a ₹92 crore impairment; similar issues could affect other products.
RISK GONE
US price erosion in generics
Pricing pressure in some key products partially offset volume gains in North America.
RISK GONE
Freight cost impact from Middle East conflict
Increased freight rates due to Red Sea route issues and air shipments added tens of crores to costs.
RISK GONE
SG&A step-up sustainability
SG&A jumped 28% YoY; analyst questioned if one-offs were included. Management attributed to investments and freight, but full-year guidance implies normalization.
RISK GONE
Cash flow moderation from factoring changes
Free cash flow was lower due to reduced factoring in the US; management expects normalization but it introduces volatility.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q3 FY24, Q4 FY24
Pricing pressure in some key products partially offset volume gains in North America.
Mentioned in Q2 FY24, Q3 FY24, Q4 FY24
Excluding divestment income, India business is expected to continue double-digit growth, driven by new product launches and partnerships.
Fast read
Guidance and risk preview
Management expects SG&A as a percentage of sales to be in the range of 27.5%-28% for the full fiscal year.
Launch of high-value products like Rituximab biosimilar in the US depends on FDA approval, which is uncertain and could be delayed.
View Risks →